Bullish Case: KMB trades at $98.55 near its Helium/market density mode (~99), yielding 5.38% with a 54-year raise streak and Q3 adjusted EPS of $1.70 beating estimates. The Kenvue acquisition closes in Q4 2026, adding ~$1.9B free cash flow and procurement/logistics synergies per COO Torres. Term structure shows near-dated Helium IV decaying from 54% to ~14% by late October, implying the panic premium unwinds as deal close and stabilization materialize.

Bearish Case: Dividends consumed 92% of free cash flow while FCF fell 35%, capex jumped 58%, and the Kenvue deal adds ~281M shares and ~$19.7B pro forma debt against a 5.24% 10-year Treasury competing for income capital. China Huggies disruption persists, organic sales fell 1.3% in Q3, $30–40M incremental freight costs hit Q4, and put skew stays steep—market density shows fat left tails toward 80–85.

Potential Outcomes:

1. Kenvue closes on schedule Q4 2026; KMB drifts 98–105 (~30%): density mode at 99, market IV flat ~25% into Dec-19 expiry (26.2%), no deal-disruption bid.
2. Post-close dividend/synergy announcement pops shares +8–12% toward 108–112 (~20%): heavy 11/06 106C/11/20 105C call volume (1,307 and 770 contracts) and Jan-2027 110C delta 0.41 flow support this.
3. Deal delay/financing stress or Q4 freight + China drag selloff to 90–93 (~25%): market density retains 0.0268 mass at 90; Helium Nov-07 IV 41.8% flags this.
4. Rangebound 95–102 chop, IV bleeds into Jan-16 expiry (~20%): term structure settles ~21–23% from Mar-2027 outward; falsified if ATM IV compresses below 20%.
5. Tail macro shock (SPY downside skew, rates stress) drives KMB below 85 (~5%): SPY surface shows IV>35 at deep downside strikes; 10/30 90P and Dec 85P/80P IVs at 34–47% price this.

October 17, 2026